228 related articles for article (PubMed ID: 31646074)
1. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Koh YW; Han JH; Haam S; Jung J; Lee HW
Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
[TBL] [Abstract][Full Text] [Related]
2. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
5. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
Li X; Chen L; Gu C; Sun Q; Li J
PeerJ; 2020; 8():e9536. PubMed ID: 32874775
[TBL] [Abstract][Full Text] [Related]
6. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
[TBL] [Abstract][Full Text] [Related]
9. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
10. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
11. Expression and Clinical Significance of
Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
[TBL] [Abstract][Full Text] [Related]
12. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
13. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
14. Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma.
Fan L; Li L; Huang C; Huang S; Deng J; Xiong J
Onco Targets Ther; 2020; 13():10075-10085. PubMed ID: 33116590
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
16. CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
Dai F; Duan YL; Feng Q; Song SL; Yang JL; Lv T
J Cancer; 2024; 15(8):2373-2379. PubMed ID: 38495487
[TBL] [Abstract][Full Text] [Related]
17. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
18. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
Qian S; Xu J; Zhao S; Yang P; Yang C
Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
